BMAL1 drives the transcription of VEGFA conferring resistance to bevacizumab treatment, therefore combining bevacizumab with a CRY2 stabilizer (SHP1705) to inhibit BMAL1 activity led to a decreased tumor volume and an improved OS in mouse models [168]. Here, CRY2 is linked to neoplasm.